 |
Previous Article | Next Article 
The Journal of Neuroscience, September 15, 2002, 22(18):7959-7967
Intron 1 Is Required for Cell Type-Specific, But Not
Injury-Responsive, Peripherin Gene Expression
Thomas E.
Uveges1,
Yuqing
Shan1,
Bridget E.
Kramer1,
David C.
Wight2, and
Linda M.
Parysek1
1 Department of Cell Biology, Neurobiology and Anatomy,
University of Cincinnati, Cincinnati, Ohio 45267-0521, and
2 Ohio University, Edison Biotechnology Institute, Konneker
Research Laboratories, Ohio University, Athens, Ohio 45701-2979
 |
ABSTRACT |
The "primitive" neurons of the peripheral nervous system (PNS)
have the remarkable ability to regenerate new fibers. This regenerative
process requires a sequence of gene activation and repression that is
poorly understood. One gene that is almost exclusively expressed in
neurons of the PNS and is activated after nerve injury is the
peripherin intermediate filament gene, but little is known about
the genomic elements that control either its restricted expression or
its response to nerve injury in adult mice. Previous studies suggested
that both 5' flanking sequence and intragenic regions were required for
cell type-specific and injury-specific expression. To determine which
intragenic regions were critical, mice were generated that expressed
peripherin transgenes lacking different introns. Analyses of these mice
revealed that deletion of introns 2-8 had no effect on either the cell
type-specific or injury-specific expression of the peripherin gene;
however, the remaining intron, intron 1, differentially bound Sp1
transcription-related proteins/protein complexes in extracts from
peripherin-expressing and nonexpressing tissues.
Furthermore, a transgene that lacked intron 1 was not expressed in many
neurons that contain endogenous peripherin but was activated after
injury. Thus, accurate cell type-specific peripherin gene expression in
the PNS depends on elements within intron 1, but other sequences, most
likely in the 5'flanking region, are required for activating the
peripherin gene in response to nerve injury.
Key words:
peripherin; gene regulation; injury-induced expression; cell type-specific expression; intermediate filament; intron; nerve
injury; Sp1; NFI
 |
INTRODUCTION |
In humans, recovery from nerve
injury is ineffective and incomplete. Those nerve fibers that
eventually regenerate are successful at sensing injury, increasing
transcription of needed components, and navigating to appropriate
targets. One strategy for improving recovery is to identify, analyze,
and ultimately enhance the molecular mechanisms that mediate these
processes. To decipher the transcriptional pathways controlling nerve
regeneration, specific genomic sequences and DNA-binding proteins that
mediate the injury response must be identified.
We are focusing on understanding these transcriptional responses by
analyzing expression of the peripherin intermediate filament (IF) gene,
one of a group of cytoskeletal genes that is transcriptionally activated after nerve injury (Oblinger et al., 1989 ; for review, see
Skene, 1989 ; Bisby and Tetzlaff, 1992 ; Tanabe et al., 1999 ). These
genes may play key roles in recovery from injury, but little is known
about the identity or hierarchy of "injury-response elements," sequences within the genes that mediate induction after injury.
Previous studies have partially localized elements that regulate
peripherin gene cell type-specific expression and activation after
nerve injury. A transgene consisting of 5.8 kb of 5' flanking sequence
linked to all peripherin exons and introns was accurately expressed in a cell type-specific manner in adult mice and was injury
responsive (Belecky-Adams et al., 1993 ). Trangenes that include
peripherin 5' flanking sequences linked to bacterial
reporter genes, however, generally have not reproduced expression of
the endogenous peripherin gene. In vitro, the 5' peripherin
flanking region activated bacterial reporter gene expression (Desmarais et al., 1992 ; Thompson et al., 1992 ), but it was not cell appropriate, leading Thompson et al. (1992) to suggest that intragenic sequences may
be required. Similarly, peripherin 5' flanking sequence
linked to lacZ restricted expression to neurons in
transgenic mice but did not promote accurate cell type-specific
expression in either embryos (Leconte et al., 1996 ) or adults
(Belecky-Adams et al., 1993 ). Addition of intragenic sequences behind a
peripherin/lacZ transgene did permit accurate expression in
mouse embryos (Leconte et al., 1996 ) but not in adult mice (B. E. Kramer, T. Belecky-Adams, and L. M. Parysek, unpublished
observations). Taken together, these findings suggest that
intragenic sequences are required for cell type-specific expression in
adult mice and that the position adjacent to the 5' flanking region may
be important. The location of injury-response elements was not reliably
determined in any of the lacZ-containing mouse lines because
the transgenes were expressed in insufficient numbers of
injury-responsive neurons in the adult.
We have undertaken studies, therefore, using a myc-tagged
rat peripherin gene as reporter, to define specific regions of the gene
critical for cell type-specific expression and for injury responsiveness in adult mice. We found that accurate cell type-specific expression of the rat peripherin gene in adult mice requires intron 1. Through in vitro footprint and binding assays on intron 1, we identified two Sp1 family member-binding sites that flank a Nuclear Factor I (NFI) family member protein-binding site. None of the
intronic sequences, however, were required for activation of the
peripherin gene after nerve injury; in this case, 5' flanking, 3'
flanking, and coding sequences were sufficient.
 |
MATERIALS AND METHODS |
Transgene construction. Transgenes were constructed
by replacing regions of the rat
Periph/periph-myc transgene (Belecky-Adams et al., 1993 ) with the corresponding region of a myc-tagged
rat peripherin cDNA. Convenient restriction sites were used to replace all peripherin genomic sequences that included introns 3-8 to make
Periph/ i3-8-myc. A similar strategy was used to make
Periph/ i2-8-myc and Periph/intronless-myc. As
with the Periph/periph-myc transgene, each transgene
contained 5.8 kb of flanking sequence, a human c-myc tag in
exon 9, and the same 600 bp of 3' flanking region (see Fig. 1).
Expression of all transgenes was tested in PC12 cells before injection
into mice.
Transgenic mice. Transgenic mice were generated and
genotyped as described in Belecky-Adams et al. (1993) . All mice tested were F1 or later generation SJL-C57BL/6 hybrids.
Immunohistochemistry. Tissues were dissected from mice of
4-8 weeks of age, embedded in TBS freeze medium (Fisher
Scientific, Pittsburgh, PA), and frozen in a dry ice-ethanol bath. The
tissue was stored at 70°C until sectioning. Seven micrometer
cryostat sections were fixed in dehydrated methanol for 4 min at
20°C and sequentially double labeled. Monoclonal antibody labeling was performed using the M.O.M. kit (Vector Laboratories Inc., Burlingame, CA), according to the kit protocol. After monoclonal labeling, polyclonal labeling was performed as described in Foley et
al. (1991) . The sections were mounted using Biomedia aqueous mounting
medium (Fisher Scientific). Primary antibodies were a rabbit polyclonal
c-myc antibody (1:100; Upstate Biotechnology, Waltham, MA), a
monoclonal peripherin antibody (1:100; Chemicon International,
Temecula, CA), and a monoclonal antibody to neurofilament-M and -H,
15G1 [neat culture supernatant; Brody et al. (1989) ]. Secondary
antibodies were goat anti-rabbit Alexa-488 (1:300; Molecular Probes,
Eugene, OR) and streptavidin conjugated to Alexa-594 (1:200; Molecular
Probes) for detection of the monoclonal antibody after M.O.M kit
labeling. Labeling was imaged using a Zeiss LSM510 confocal laser-scanning microscope. The nerve crushes were performed as described in Belecky-Adams et al. (1993) , except that tissues were
placed in TBS freeze medium and analyzed as described above.
Nuclear extracts. Isolation of nuclear extracts was
performed as described in Dusing et al. (2001) , except that KCl
replaced NaCl in buffer C, and
N-acetyl-L-cysteine was not used for
extract preparation from the brain and liver. For each nuclear extract isolation procedure, the entire mouse small intestine, brain, or liver
was used from each of eight mice.
Whole-cell extracts. All solutions were used at 4°C and
contained 5 mM PMSF (Sigma, St. Louis, MO), 1 mM leupeptin (Sigma), and 1 mM pepstatin A (Sigma). All dorsal root ganglia
(DRGs) down to L4 (~40) were dissected from each of four mice and
placed into 1 ml of PBS. They were washed once in PBS and then treated
with 0.5% collagenase (Worthington, Lakewood, NJ) for 30 min at
37°C. The cells were washed in PBS and pelleted. The cells were then resuspended in lysis buffer (20 mM HEPES-KOH, pH
7.9, 450 mM NaCl, 0.4 mM
EDTA, 0.5 mM DTT, 25% glycerol). Cells were
placed three times in a dry ice-ethanol bath for 2 min and then put at
37°C for 2 min. Subsequently, they were spun for 10 min at 4°C. The supernatant was removed and frozen at 80°C (Dent and Latchman, 1993 ).
Electrophoretic mobility shift assay. Gel-purified
double-stranded oligonucleotides at 2.25 nM were
labeled at one end by use of a Klenow-mediated (NEB, Beverly, MA)
fill-in reaction with dATP -32P (3000 Ci/mmol) at a 5' overhang. Labeled oligonucleotide was purified on a
nick column (Amersham Biosciences, Piscataway, NJ). Binding reactions
of 25 µl contained 5 µl of 5× buffer (125 mM Tris, pH 8.0, 32.5 mM
MgCl2, 2.5 mM DTT, 2.5 mM EDTA, 250 mM KCl, and
0.6 µg/µl BSA), 0.5 µl of 4 µg/µl of poly I/poly C (Sigma), 0.5 µl of 5 M NaCl, 10 µl of nuclear extract
or whole-cell extract diluted with Buffer D [20
mM HEPES-KOH, pH 7.9, 20% glycerol, 0.1 M KCl, 0.2 mM EDTA, 5 mM PMSF (Sigma), 1 mM
leupeptin (Sigma), and 1 mM pepstatin A (Sigma)
and 0.5 mM DTT], and 100× molar excess of
competitor oligonucleotide (in reactions containing inhibitors) plus
water to a final volume of 24 µl. One microliter of labeled oligonucleotide (15,000-30,000 cpm) was added and incubated for 30 min
on ice. One microliter of loading dye was added, and the entire
reaction was run on a 5.7% nondenaturing polyacrylamide gel at 30 mA
in 1× TBE. Gels were dried under vacuum and exposed to x-ray film
overnight. Each experiment was repeated with extracts from different
nuclear protein isolations.
DNA footprint. Overlapping PCR fragments spanning the length
of intron 1 were labeled at one end by use of a Klenow-mediated fill-in
reaction with dATP -32P (3000 Ci/mmol)
at a 5' overhang created by restriction digest. The labeled fragments
were purified on a nick column (Amersham Biosciences). Twenty-five
microliters of nuclear extract or whole-cell extract in Buffer D
[formulated as for electrophoretic mobility shift assay (EMSA)] were
incubated on ice for 30 min with 10 µl of 5× buffer (125 mM HEPES-KOH, pH 7.9, 25 mM
MgCl2, 5 mM DTT, and 0.5 µg/µl of BSA), 1 µl of 1 µg/µl of poly I/poly C, 0.5 µl of
5 M NaCl, and 13.5 µl of water to a final
volume of 50 µl. Control reactions were incubated with BSA in the
place of nuclear extract. Labeled probe was added (0.5-1 ng;
100,000-150,000 cpm) and incubated on ice for 1 hr. DNase I, at a
concentration of 0.05 Kunitz units, was added to each reaction mixture
and incubated for 1 min at 25°C. One hundred fifty microliters of
ice-cold stop solution (15 mM EDTA, 0.2% SDS, 40 µg/ml of salmon sperm DNA, and 20 mg/ml of proteinase K) were added.
The tubes were then incubated at 50°C for 20 min. Each reaction was
phenol-chloroform extracted three times and ethanol precipitated. The
samples were resuspended in 2 µl of water and 4.5 µl of sequencing
stop dye (95% formamide, 10 mM EDTA, 0.05%
bromophenol blue, and 0.1% xylene cyanol). The products were denatured
and run on a 6% polyacrylamide gel (Sequagel 6, National Diagnostic,
Atlanta, GA). The gel was dried and placed on x-ray film overnight.
Each experiment was repeated with extracts from different nuclear
protein isolations. Size standards were obtained by Sequenase reactions
(USB, Cleveland OH) prepared by the provided protocol.
 |
RESULTS |
To define regions of the peripherin gene that are critical for
cell type-specific expression and activation in response to nerve
injury in adult mice, we deleted sequential segments from a correctly
expressed full-length rat peripherin genomic construct (Fig.
1, Periph/periph-myc). We
decided against the use of lacZ reporter-based constructs because our
unpublished studies indicated that a lacZ reporter flanked by
intragenic sequences was not expressed reliably in adult mice (Kramer,
Belecky-Adams, and Parysek, unpublished observations). The structure of
the first construct for our current studies was guided by previous
observations that only introns 1 and 2 contain significant sequences
identical in rat, mouse, and human (Foley et al., 1994 ). Thus, the
first construct contained 5.8 kb of rat peripherin 5'
flanking sequence driving a rat peripherin gene that lacked introns
3-8 (Fig. 1, Periph/ i3-8-myc). A second construct,
Periph/ i2-8-myc, was identical to the first but lacked intron 2 (Fig. 1). A third transgene contained the entire
peripherin coding region but no introns (Fig. 1,
Periph/intronless-myc). To facilitate detection of the
transgene-derived protein, an in-frame myc tag was placed at
the 3' end of these transgenes.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 1.
Rat peripherin transgenes. The open
boxes represent 5.8 kb of 5' flanking sequence (to scale), the
solid shaded boxes represent peripherin exons
(to scale), and solid lines represent intronic sequences
(intron numbers below) and 3' flanking sequence (to scale). A human
c-myc tag (v) was placed in-frame at the 3'
end of the coding region in exon 9 to facilitate detection of protein
derived from each transgene.
|
|
Introns 3-8 are not required for accurate cell type-specific
expression of peripherin
We tested the effects on cell type-specific expression in adult
mice of deleting introns 3-8 (Periph/ i3-8-myc) from a
full-length rat peripherin transgene. This transgene was introduced
into the genome of six lines of mice, five of which expressed
myc-tagged peripherin protein. Double immunofluorescence revealed that
distribution of myc-tagged transgenic protein was identical to that of
endogenous peripherin protein in sensory neurons of the DRG, enteric
nervous system, and lower motor neurons, all areas that exhibit
distinctive patterns of peripherin expression (Portier et
al., 1984 ; Parysek and Goldman, 1988 ). In DRG neurons, myc
labeling was seen in small-diameter neurons but was not detectable in
the large-diameter neurons, matching the distribution pattern of
endogenous protein (data not shown). In the small intestine, both
transgenic and endogenous proteins were observed in the enteric ganglia
of the myenteric and submucosal plexuses, and in the spinal cord, all
peripherin-expressing lower motor neurons coexpressed
transgenic protein (data not shown). In addition, in regions of the
brain and brainstem examined, the transgene was expressed in cells that
express endogenous peripherin, and not in any other neurons
(data not shown). These expression patterns were essentially identical
to that seen with the full-length peripherin transgene (Belecky-Adams
et al., 1993 ) and indicated that introns 3-8 are not required for
accurate cell type-specific expression of peripherin.
Because intragenic sequences were required for regulation of the
peripherin gene in adult mice (Belecky-Adams et al., 1993 ), further
experiments focused on the remaining introns, 1 and 2.
Intron 2 is not required for cell type-specific
peripherin expression
To test the role of intron 2, a transgene lacking introns 2-8
(Periph/ i2-8-myc) was analyzed. Six lines expressed the
myc-tagged transgenic protein of nine lines that incorporated the
transgene. As with the Periph/ i3-8-myc transgenic lines,
expression of the Periph/ i2-8-myc transgene was
identical to that of endogenous peripherin in these six
lines. The distribution of transgenic protein and endogenous protein
was virtually identical in the sensory neurons of the DRG (Fig.
2A,B),
the enteric nervous system (Fig.
3A,B),
and the lower motor neurons of the cervical spinal cord (Fig.
4A,B).
These data indicate that intron 2 does not contain sequences critical
for precise cell type-specific expression of the peripherin gene,
suggesting that these control elements are likely contained within
intron 1.

View larger version (118K):
[in this window]
[in a new window]
|
Figure 2.
Intron 1 is required for cell type-specific
expression of peripherin transgenes in the DRG. Cross sections of adult
DRGs from Periph/ i2-8-myc (A,
B) and Periph/intronless-myc
(C, D) transgenic mice were double
labeled with a polyclonal myc antibody (A,
C) and a monoclonal peripherin antibody
(B, D) to determine whether the
transgenic protein pattern matched the endogenous pattern. In DRG
sections from intron 1-containing mice, essentially perfect overlap was
observed between the transgenic protein and endogenous
peripherin (A, B), but DRGs
from the intron 1-deleted transgenic mice revealed that many
neurons expressed endogenous peripherin (D) but
did not express transgenic peripherin (C). Scale
bar, 20 µm.
|
|

View larger version (93K):
[in this window]
[in a new window]
|
Figure 3.
Intron 1 is required for cell type-specific
expression of peripherin transgenes in the enteric nervous system.
Cross sections of adult small intestine were double labeled with
polyclonal myc antibody (A, C) and
monoclonal peripherin antibody (B, D) to
determine whether transgenes were expressed in endogenous
peripherin-expressing neurons in the myenteric (white
arrows) and submucosal (white arrowheads)
plexuses. Expression of the intron 1-containing transgene,
Periph/ i2-8-myc, perfectly matched endogenous
peripherin expression (A, B),
but the Periph/intronless transgene (C,
D) was expressed in <50% of the peripherin-positive
structures in both the myenteric and submucosal plexuses in a majority
of the lines. Scale bar, 20 µm.
|
|

View larger version (138K):
[in this window]
[in a new window]
|
Figure 4.
Cell type-specific expression of
peripherin in lower motor neurons requires intron 1. Cross sections of adult mouse cervical spinal cord were double labeled
with a polyclonal myc antibody (A, C) and
a monoclonal peripherin antibody (B, D)
to determine the degree of overlap between transgenic and endogenous
protein. In the intron-1 containing Periph/ i2-8-myc
transgenic mice (A, B, white
arrows), transgene expression mimics that of endogenous
peripherin, but in most of the
Periph/intronless transgenic mice, the only evidence of
transgene expression in the lower motor neurons (C,
D, white arrowheads) was an
occasional labeled fiber in the ventral root (C,
D, open arrows). Scale bar, 20 µm.
|
|
Intron 1 contains elements required for accurate cell type-specific
expression of peripherin
To determine directly whether intron 1 is required for peripherin
gene regulation in adult mice, expression of a transgene lacking all
introns (Periph/intronless-myc) was analyzed. Because genomic elements surrounding transgene integration sites can unduly limit the basal expression of transgenes lacking introns (Choi et al.,
1991 ; Webster et al., 1997 ), we examined an exceptionally large number
of lines containing the intronless peripherin
transgene. Seventeen lines of mice were generated that carried the
transgene, and 11 of these lines (64.7%) were found to express
transgenic protein. Approximately the same percentage of lines
expressed the intron 1-containing transgene
(Periph/ i2-8-myc) (66.7%), suggesting that absence of
an intron in the transgene did not have a significant impact on its
basal expression.
In striking contrast to transgenic lines that contained intron 1, expression of transgenic protein varied significantly among the 11 expressing lines of intronless mice. No line had an overall distribution pattern identical to that of endogenous peripherin, although in some cases, expression among neurons of the DRG was close
to normal. In DRG sensory neurons, myc-tagged protein was detected in
each of the 11 expressing lines of mice, but only 3 lines showed
reasonably good correspondence (75-85%) to endogenous expression, and
in each case, myc-negative cells belonged to the medium-sized neuron
size class. In these same three lines, however, the transgene was not
expressed at all in enteric neurons. Four other lines expressed
myc-tagged protein in ~50% of the peripherin-positive DRG neurons
(Fig. 2C,D), and the remaining four lines
expressed transgenic protein in <50% of peripherin-positive neurons.
These data are consistent with the idea that intron 1 contains an
enhancer required for complete peripherin expression in the
DRG. In some lines, sequences surrounding the integration site may
compensate, to a degree, for the loss of the enhancer, but expression
identical to endogenous peripherin was obtained only when
intron 1 was present.
In the enteric nervous system, dramatic differences were observed
between expression of the intronless transgene and
endogenous peripherin gene. Of the 11 expressing lines, 8 lines
expressed the transgene in the gut, but none of these lines expressed
the transgene in all peripherin-positive neurons. In four lines,
transgene was expressed in >50% of peripherin-positive structures in
the myenteric and submucosal plexuses. In the other four lines, the transgene was expressed in >50% of myenteric structures, but in much
less than 50% of submucosal structures, leading to an overall expression level of <50% of peripherin-positive structures in the
enteric nervous system (Fig. 3C,D). Thus, the
expression pattern of the intronless transgene indicated the
presence of regulatory sequences within intron 1 critical for correct
peripherin gene expression in the enteric nervous system.
Differences also were observed between expression of the endogenous
peripherin gene and the intronless transgene in lower motor
neurons of the cervical spinal cord, indicating that sequences in
intron 1 play a critical role in regulating peripherin gene expression
in these cells as well. Myc-tagged protein was observed in the cervical
cord in all 11 intronless lines, but in no more than 50% of
motor neurons in four lines and only in rare neurons in the remaining
seven lines, indicated by the presence of one or two myc-labeled fibers
in the ventral root (Fig. 4C,D). Examination of
other areas of the CNS, parts of the brain and brainstem, revealed similar findings as in the PNS; that is, loss of intronless
transgene expression in some peripherin-positive neurons and no ectopic expression.
In summary, these data revealed that deletion of intron 1, but not the
other seven peripherin gene introns, results in loss of transgene
expression in some cells that express endogenous peripherin. Intron 1, therefore, must contain elements critical for full expression of the
peripherin gene.
Which regions of intron 1 are responsible for cell
type-specific regulation?
To identify specific sequences in intron 1 that may be responsible
for regulating cell type-specific expression of peripherin, DNase I footprint analyses were performed. Addition of nuclear extracts
from the small intestine, brain, or liver or whole-cell extracts from
the DRG inhibited DNase I degradation of five regions within intron 1 (Figs. 5,
6, 7).
These regions were located at rat gene [(GenBank Accession no. M26232;
Thompson and Ziff (1989) ] nucleotides 1483-1493 [Footprint (FP) 1],
1528-1537 (FP2), 1546-1555 (FP3), 1678-1686 (FP4), and 1697-1707
(FP5) (Fig. 5, top). To confirm that the footprints
represented specific protein-DNA interactions, EMSAs were performed
using oligonucleotides of appropriate length (>25 bp) for the
assays.

View larger version (46K):
[in this window]
[in a new window]
|
Figure 5.
Extracts from tissues that express peripherin
contain different intron 1-binding Sp1 or Sp1-related proteins than
nonexpressing tissues. A region of intron 1, from 1360-1664 of the rat
peripherin gene, was radiolabeled and digested with DNase I in the
presence of BSA (Control), whole-cell extract
from the DRG, or nuclear extract from the small intestine
(SI), brain, or liver. Nuclear extracts from all
tested tissues protected nucleotides 1483-1493, footprint 1 (FP1) (A). EMSA of Oligo 1, corresponding to FP1 and surrounding sequences, illustrated specific
DNA-protein complexes with nuclear extract from the SI
(left, arrowhead) and liver
(right). These complexes were competed off by unlabeled
Oligo 1 (Specific), a short oligonucleotide
(Oligo 1B) to the protected sequence, and by an
oligonucleotide containing an Sp1 consensus site. The formation of
these complexes was not inhibited by a nonspecific oligonucleotide or
by an oligonucleotide containing a mutant Sp1 consensus site
(B) (Oligo sequences are shown in Table 1).
|
|

View larger version (46K):
[in this window]
[in a new window]
|
Figure 6.
Intron 1 interacts with different NFI- or
NFI-related proteins, depending on whether the tissue extract of origin
contains neurons. Sequence from 1475-1594 of the rat peripherin gene
was radiolabeled and digested with DNase I in the presence of BSA
(Control), whole-cell extract from the DRG, or
nuclear extract from the small intestine (SI),
brain, or liver. Nucleotides 1528-1537 (FP2) and
1546-1555 (FP3) were protected by extracts from all
tissues (A). Oligo 2, containing FP2 and FP3 and
surrounding nucleotides, formed specific DNA-protein complexes with
extracts from the DRGs (B). These complexes were
competed off by unlabeled Oligo 2 (Specific), an
oligonucleotide (Oligo 2B) containing sequence between
FP2 and FP3, and by an oligonucleotide containing an NFI consensus
site. These complexes were not inhibited by a nonspecific
oligonucleotide, Oligo 2A, Oligo 2C, Oligo 2D, or an oligonucleotide
containing a mutant NFI consensus site.
|
|

View larger version (55K):
[in this window]
[in a new window]
|
Figure 7.
A second site in intron 1 binds Sp1 or Sp1-related
proteins that correlate with the status of peripherin expression in the
tissue from which the extract was derived. A region spanning 1665-1800
of the rat gene was radiolabeled and digested with DNase I in the
presence of BSA (Control), whole-cell extract
from the DRG, or nuclear extract from the SI, brain, or liver. There
was protection of nucleotides 1678-1686 (FP4)
and 1697-1707 (FP5) by extracts from all tissues
(A). An oligonucleotide containing FP4, FP5, and
surrounding sequences formed specific DNA-protein complexes with
whole-cell extract from the DRG (B,
arrowhead) and nuclear extract from the liver
(C). These complexes were competed off by
unlabeled Oligo 3 (Specific) and by an oligonucleotide
containing an Sp1 consensus site. The liver nuclear extract formed one
complex that was reduced, but not completely competed off, by the Sp1
oligonucleotide. All complexes were not inhibited by a nonspecific
oligonucleotide or by an oligonucleotide containing a mutant Sp1
consensus site (B, C).
|
|
The first experiment focused on FP1 (Fig. 5A) and used an
oligonucleotide (Oligo 1) that contained FP1 and adjacent nucleotides (Table 1; see Sequence). The mobility of
Oligo 1 was reduced when incubated with whole-cell extract from mouse
DRG (data not shown) or nuclear extracts from small intestine (Fig.
5B, left), liver (Fig. 5B,
right), or brain (data not shown). To show that the
DNA-protein interactions were specific, EMSAs using competitor oligonucleotides were performed. These experiments showed that the
DNA-protein complexes were specific because a specific inhibitor, excess unlabeled Oligo 1, blocked the formation of the DNA-protein complexes, and excess nonspecific inhibitor had no effect on complex formation. Extracts from DRGs or small intestine formed a single high-mobility complex (Fig. 5B, left,
arrowhead). In contrast, nuclear extracts from liver (Fig.
5B, right) or brain (data not shown) resulted in
several complexes of lower mobility, suggesting that these tissues
contain multiple proteins interacting at this site. To define the exact
location of protein interaction, short Oligos 1A, 1B (corresponds to
FP1), and 1C (Table 1; see Sequence) were used in competitive binding
experiments. These assays showed that only Oligo 1B competed for
binding, indicating that the regions of protein binding in Oligo 1 resided completely within the region protected in DNA footprint
analysis. Using the Transcription Element Search System (TESS) sequence
analysis database, computer analysis of FP1 revealed the presence of a
potential Sp1 binding site. To determine whether an Sp1 family member
does interact with this sequence, an oligonucleotide containing an Sp1
consensus binding site and an identical oligonucleotide containing a
mutant Sp1 binding site (Table 1; see Sequence) were tested for their
ability to compete with labeled Oligo 1 for binding to nuclear protein. Excess Sp1 oligonucleotide greatly reduced or eliminated binding of
protein from all tissues to labeled Oligo 1, whereas excess mutant Sp1
oligonucleotide did not, signifying that members of the Sp1 family of
transcription factors interact with this sequence.
A second oligonucleotide, Oligo 2 (Table 1; see Sequence), spanning
footprinted regions 2 (FP2) and 3 (FP3) (Fig. 6A) and adjacent nucleotides, showed an identical high-mobility shift when
incubated with whole-cell extract from mouse DRGs (Fig.
6B) or nuclear extract from the small intestine or
brain (data not shown). Nuclear extract from a non-neuronal tissue,
liver, produced multiple lower-mobility protein-DNA complexes (data
not shown). Formation of complexes from all tissue extracts was
abolished by addition of excess unlabeled Oligo 2 (specific inhibitor)
but not by excess nonspecific oligonucleotide. Short competitor Oligos 2A, 2B, 2C, and 2D (Table 1; see Sequence), spanning the length of
Oligo 2, indicated protein bound to nucleotides 1539-1551 (Oligo 2B),
which is located between FP2 and FP3. Computer analysis of nucleotides
1539-1551, using the TESS sequence analysis program, indicated a
potential NFI binding site. To determine whether NFI protein family
members in the tissue extracts interacted with Oligo 2, competitive
oligonucleotides containing either an NFI consensus site or a mutant
NFI consensus site (Table 1; see Sequence) were tested for their
ability to inhibit binding of the extract to labeled Oligo 2. The NFI
consensus oligonucleotide inhibited binding of all proteins from DRGs
(Fig. 6B), small intestine, brain, and liver (data
not shown), but the mutant NFI oligonucleotide did not interfere with
these interactions (Fig. 6B). These data indicate
that NFI family member proteins bind to the 1539-1551 region of the
rat peripherin gene. Although the EMSAs localized the protein-DNA
interaction to an NFI consensus site, the footprint results suggest an
area of protein binding localized outside of this area. Because these
assays use the same extracts but are done under very different
conditions, it is likely that an NFI or a related protein is a critical
member of a multiple protein complex that interacts with the entire
region between nucleotides 1528 and 1555 of the rat peripherin gene.
A single high-mobility protein-DNA complex also was formed when Oligo
3 (Table 1; see Sequence), corresponding to footprinted regions 4 (FP4)
and 5 (FP5) (Fig. 7A) and adjacent nucleotides, was
incubated with whole-cell extract from mouse DRGs (Fig. 7B, arrowhead) or nuclear extract from the small intestine (data
not shown). This interaction was specific, because unlabeled Oligo 3 (specific inhibitor) abolished the interaction, whereas nonspecific inhibitor had little effect. Nuclear extracts from liver (Fig. 7C) or brain (data not shown) formed multiple low-mobility
DNA-protein complexes. These interactions also were specific because
they were eliminated by unlabeled Oligo 3 (data not shown) but not by a
nonspecific inhibitor. Sequence analysis showed that Oligo 3 contains a
perfect Sp1 motif. To confirm binding of an Sp1 family member protein
to this site, Sp1 and mutant Sp1 oligonucleotides were tested to
determine their efficiency in competing for the interaction between the
protein and labeled Oligo 3. The Sp1 oligonucleotide completely
inhibited all interactions in all tissue extracts (Fig. 7B),
except for one partially inhibited protein-DNA complex formed by liver
nuclear extract (Fig. 7C). The mutant Sp1, however, did not
inhibit any interactions, confirming that Sp1 family member proteins
interact with this region of intron 1 (Fig.
7B,C).
Taken together, the data indicate that intron 1 is required for
regulating accurate cell type-specific expression and that known
transcription factor family proteins bind to intron 1.
Intragenic sequences are not required for activation of
peripherin after nerve injury
To determine whether intron 1 was required for activation of the
peripherin gene after nerve injury, transgene expression was studied
after sciatic nerve crush in the intron 1-containing Periph/ i2-8-myc lines and in the intron 1-deleted
Periph/intronless-myc lines that expressed the peripherin
transgene in a near-perfect manner in the DRGs. Seven days after
injury, expression of the transgene was assessed by
myc-immunofluorescence. Expression of endogenous peripherin
was assayed as a positive control. In each experiment, sham-operated
mice were used as a negative control.
Analyses of nerve crush experiments performed on the
Periph/ i2-8-myc transgenic line of mice revealed an
increase in peripherin transgene expression that paralleled the normal
increase in endogenous peripherin gene expression (data not shown) in
large-diameter sensory neurons of the DRG after injury. After the sham
operation, the large-diameter neurons expressed minimal or no
peripherin (data not shown), as is normal for the uninjured DRG. These
initial studies revealed that introns 2-8 were not required for
injury-induced peripherin gene activation.
Similarly, in the Periph/intronless-myc transgenic mouse
lines that expressed transgene-derived peripherin/myc in 75-85% of the peripherin-positive neurons, myc-tagged protein was expressed robustly in large-diameter neurons after nerve crush (Fig.
8A, arrows),
paralleling the increase in endogenous peripherin expression (Fig.
8B, arrows). No increase was observed in
sham-operated animals (Fig. 8C,D,
arrows). This increase in myc-tagged protein was observed in
85% of the large-diameter neurons in this ganglion, as determined by
comparing neurofilament and myc labeling (data not shown). Importantly,
the percentage of large-diameter neurons expressing transgenic protein
was identical to the percentage of cells expressing endogenous
peripherin protein, indicating that the intronless transgene
was activated in the appropriate neurons. These data indicate that
injury response elements are not located within the introns but are
most likely located in the 5' flanking sequence, although the
possibility that they are located in the 3' untranslated region or
exons of the peripherin gene cannot be excluded.

View larger version (119K):
[in this window]
[in a new window]
|
Figure 8.
Intron 1 is not required to activate
peripherin expression after nerve injury.
Periph/intronless-myc transgenic mice that expressed the
transgene in 85% of endogenous peripherin-expressing neurons underwent
either sciatic nerve crush (A, B) or
surgery alone (sham operated) (C, D).
Cross sections of the L5 DRG from these mice, which were double labeled
with polyclonal myc antibody (A, C) and
monoclonal peripherin antibody (B, D),
revealed that the Periph/intronless-myc transgene was
upregulated after injury in a manner identical to that of endogenous
peripherin. Both transgenic and endogenous peripherin
protein were expressed in the large-diameter sensory neurons of injured
mice (A, B, arrows) but
not in these neurons in the uninjured DRGs (C,
D, arrows). Scale bar, 20 µm.
|
|
 |
DISCUSSION |
To understand the transcriptional pathways leading to activation
of the peripherin gene after nerve injury, we identified genomic
segments required for cell type-specific expression and induction after
nerve injury. We found that 5.8 kb of 5' peripherin flanking sequence
was sufficient for injury-induced activation of an intronless
peripherin gene that contained peripherin coding and 600 bp 3' flanking
sequence, but was insufficient to direct transgene expression to all
peripherin-expressing neurons. Only transgenes that also contained
intron 1 were expressed in all of the same neurons that express
endogenous peripherin. Thus, injury-inducible elements are
likely to lie in the 5' flanking region but also could be located in
the 3' untranslated region or coding region, whereas critical
cell-specific elements lie in intron 1.
The intron 1-dependent loss of transgene expression from some cells
that express endogenous peripherin suggests that intron 1 contains one or more enhancer elements that are not of the general enhancer type. Loss of a general enhancer would be expected to reduce
expression levels overall and result in an apparent preferential loss
of transgene-derived peripherin in neurons that normally express low
levels of endogenous peripherin. This is not what we observed. Instead,
in mice bearing the intronless transgene, cells that
appeared to be labeled similarly by peripherin antibody [such as the
small-sized DRG cells (Fig. 8D, top) or
the myenteric elements (Fig. 3D, bottom)] were
dissimilarly labeled by myc antibody (corresponding regions of Figs.
8C and 3C, respectively), indicating that
transgene expression was lost only from certain cells. This enhancer
appeared to be especially important for expression in medium-sized DRG
neurons, the submucosal enteric neurons, and lower motor neurons of the
spinal cord, suggesting that the element is more in the nature of a
cell type-specific, rather than general, enhancer.
Two additional conclusions can be drawn about the role of intron 1. First, it is clear that it plays no role in restricting expression to
peripherin-positive neurons. Whether intron 1 was present or not, we
never observed ectopic expression of any of the peripherin transgenes,
even in the brain (data not shown). Second, intron 1 does not contain
an "all-or-none" enhancer because deletion of intron 1 impaired
expression in every 1 of 17 mouse lines with distinct transgene
integration sites, yet did not abolish all peripherin expression. Thus,
intron 1 is critical, but it is likely to be aided in executing its
enhancer function by the 5' flanking sequence, exons, or the 3'
untranslated region.
EMSA analysis identified candidate sequences within intron 1 that are
likely to play roles in the cell-type-specific expression of
peripherin. Two Sp1 consensus sites bound distinct proteins or protein complexes that correlated with peripherin expression in the
tissue extract of origin. Extracts from tissues that expressed robust
amounts of peripherin (DRGs, small intestine) formed a single,
high-mobility complex with each of the two Sp1 sites. It is most likely
that this high-mobility complex contained an uncommon, perhaps
tissue-specific, Sp1 family member or unknown protein because binding
of Sp1 itself or a closely related protein to DNA produces multiple
complexes with lower mobility shifts (Andrew et al., 2000 ; Teunissen et
al., 2002 ) such as we observed with extracts derived from tissues that
expressed little or no peripherin (liver and brain). Similarly,
extracts from neuron-enriched tissues (brain, small intestine, and
DRGs) formed a single complex with the NFI site in intron 1 that was
very different from the multiple complexes formed by proteins from
liver. As yet, we have no direct evidence that this Sp1/NFI/Sp1 motif
is required for cell-type-specific expression of peripherin,
but the close correlation between the type of complex formed and the
origin of the tissue extract strongly supports this conclusion.
Previous work on the mouse peripherin gene by Lecomte et al. (1999)
also supports the importance of these Sp1 sites in peripherin gene
regulation. Mouse neuroblastoma cell nuclear extract bound to a core
Sp1 motif in intron 1 of the mouse peripherin gene that is 90%
identical in sequence to our first Sp1 binding site (1483-1493 of the
rat gene). The binding protein was identified as "AP-2-like" but
was not characterized. Lecomte et al. (1999) also observed binding of a
member of the Sp1 family to a region of the mouse gene that is
identical in sequence to our second Sp1 site (1678-1686). TESS
sequence analyses indicate that both Sp1 sites are conserved in the
human gene as well, suggesting that Sp1 or related proteins that
interact with this region of intron 1 in rat and mouse also interact
with the same sites in the human gene. There are several theories about
the role of Sp1 (for review, see Fry and Farnham, 1999 ) and NFI (for
review, see Gronostajski, 2000 ) or related proteins in regulating gene
transcription when present in the promoter, but how they may function
together when present within an intron remains unknown. The role of the
Sp1 and NFI sites in intron 1 of the peripherin gene will be determined
by testing the effect of mutating these sites on peripherin
expression in transgenic mice.
Our finding that intron 1 of the peripherin gene contains elements
required for cell-type-specific expression adds to previous studies
showing the importance of intron 1 for precise cell type-specific and
temporal expression of other IF genes, including those encoding glial
fibrillary acidic protein (Sarkar and Cowan, 1991 ), keratin 18 (Rhodes
and Oshima, 1998 ), neurofilament-L (Charron et al., 1995 ), and nestin
(Zimmerman et al., 1994 ). Given the common evolutionary origin of the
IF genes, some consistency in location of key regulatory elements might
be expected. Interestingly, perfect Sp1 and NFI consensus sites are
found in intron 1 of the neurofilament-L gene (Charron et al., 1995 ) in
an arrangement similar to that in the peripherin gene. These
observations raise the possibility that primitive Sp1 and NFI
recognition sequences present in the evolutionary antecedent of the IF
genes may have been duplicated along with the structural genes and then
evolved to mediate distinct patterns of cell-type-specific expression
through interaction with different Sp1 and NFI family members.
Intron 1 is critical for full expression of peripherin transgenes in
peripherin-expressing neurons, but the observation that an
intronless transgene was activated by nerve injury suggests that
required injury-response elements are not present in intragenic regions. This finding was somewhat unexpected because our previous studies (Belecky-Adams et al., 1993 ) indicated that 5' flanking sequence of peripherin was insufficient to activate a lacZ
reporter gene after nerve injury. In that study, however, the lacZ
reporter construct was either not expressed at all or poorly expressed in injury-responsive neurons (Belecky-Adams et al., 1993 ). The intronless myc-tagged peripherin transgene used in the present studies
was expressed more robustly in mice, and three lines expressed this
transgene at high levels in DRG neurons, allowing a more reliable test
of injury responsiveness. The observation that this intronless
transgene was activated after nerve injury suggests that the
injury-response elements are located within the 5' region, although the
coding sequences or 3' flanking sequences of the gene cannot yet be
completely excluded. Indeed, injury-mediated repression of mRNA
encoding neurofilament-L occurs via elements in the 3' untranslated
region (Schwartz et al., 1995 ). Both 5' flanking sequence and a minimum
of 11 kb of intron 1 are needed for accurate cell type-specific
regulation and activation after injury of the GAP-43 gene (Vanselow et
al., 1994 ), which, like peripherin, shows an injury-mediated increase
in mRNA (Woolf et al., 1990 ). The precise location of the
GAP-43 injury-response elements, however, remains unknown.
The identification of intron 1 as critical for full cell-type specific
expression facilitates the design of transgenes for determining 5'
flanking sequences required for activation after injury. Several
potential regulatory sequences, including NGF-inducible and
IL-6-binding elements, have been identified within the 5' flanking
sequence of peripherin via in vitro studies
(Thompson et al., 1992 ; Lecomte et al., 1998 ). NGF activator domains
lie both distal and proximal to the TATA box (Thompson et al., 1992 ; Desmarais and Royal, 1996 ), and NGF is believed to be a primary activator of the peripherin gene (Leonard et al., 1987 ), but this has
not been verified in vivo. Significantly, functional
recovery after nerve regeneration is an NGF-independent process
(Diamond et al., 1992 ). Thus, activation of the peripherin gene after
nerve crush might not require NGF. We believe that the IL-6 element is
a particularly good candidate for an injury-response element. IL-6
activates the peripherin gene (Sterneck et al., 1996 ; Lecomte et al.,
1998 ), it is induced in Schwann cells within 12 hr after nerve injury
(Bolin et al., 1995 ), making it readily available during regeneration,
and it increases the rate of regeneration of peripherin-positive
neurons (Hirota et al., 1996 ; Shuto et al., 2001 ). Furthermore, the
location and sequence of the binding site for LIF/IL-6 are highly
conserved in the mouse and human peripherin genes. The role of the IL-6
site and other potential sites in injury responsiveness can now be
tested through further deletion analyses. Once such elements in the
peripherin gene have been defined, it will be important to determine
whether they are shared among other nerve injury-activated genes.
 |
FOOTNOTES |
Received April 11, 2002; revised June 24, 2002; accepted June 27, 2002.
This work was supported by Grant 35313 from the National Institute of
Neurological Disorders and Stroke. We thank Dr. Dan Wiginton for his
advice and guidance with the DNase I footprinting and EMSA experiments,
Molly McFarland for her help with construction of the deletion
transgenes, and Dr. Robert Brackenbury for helpful comments on this manuscript.
Correspondence should be addressed to Dr. Linda M. Parysek, Department
of Cell Biology, Neurobiology and Anatomy, University of Cincinnati,
3125 Eden Avenue, Cincinnati, OH 45267-0521. E-mail: Linda.Parysek{at}uc.edu.
 |
REFERENCES |
-
Andrew SD,
Delhanty PJ,
Mulligan LM,
Robinson BG
(2000)
Sp1 and Sp3 transactivate the RET proto-oncogene promoter.
Gene
256:283-291[ISI][Medline].
-
Belecky-Adams T,
Wight DC,
Kopchick JJ,
Parysek LM
(1993)
Intragenic sequences are required for cell type-specific and injury-induced expression of the rat peripherin gene.
J Neurosci
13:5056-5065[Abstract].
-
Bisby MA,
Tetzlaff W
(1992)
Changes in cytoskeletal protein synthesis following axon injury and during axon regeneration.
Mol Neurobiol
6:107-123[ISI][Medline].
-
Bolin LM,
Verity AN,
Silver JE,
Shooter EM,
Abrams JS
(1995)
Interleukin-6 production by Schwann cells and induction in sciatic nerve injury.
J Neurochem
64:850-858[ISI][Medline].
-
Brody BA,
Ley CA,
Parysek LM
(1989)
Selective distribution of the 57 kDa neural intermediate filament protein in the rat CNS.
J Neurosci
9:2391-2401[Abstract].
-
Charron G,
Guy LG,
Bazinet M,
Julien JP
(1995)
Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain.
J Biol Chem
270:30604-30610[Abstract/Free Full Text].
-
Choi T,
Huang M,
Gorman C,
Jaenisch R
(1991)
A generic intron increases gene expression in transgenic mice.
Mol Cell Biol
11:3070-3074[Abstract/Free Full Text].
-
Dent CL,
Latchman DS
(1993)
The DNA mobility shift assay.
In: Transcription factors: a practical approach (Latchman DS,
ed), pp 1-26. New York: Oxford UP.
-
Desmarais D,
Royal A
(1996)
The TATA motif is a target for efficient transcriptional activation and nerve growth factor induction of the peripherin gene.
J Biol Chem
271:24976-24981[Abstract/Free Full Text].
-
Desmarais D,
Filion M,
Lapointe L,
Royal A
(1992)
Cell-specific transcription of the peripherin gene in neuronal cell lines involves a cis-acting element surrounding the TATA box.
EMBO J
11:2971-2980[ISI][Medline].
-
Diamond J,
Foerster A,
Holmes M,
Coughlin M
(1992)
Sensory nerves in adult rats regenerate and restore sensory function to the skin independently of endogenous NGF.
J Neurosci
12:1467-1476[Abstract].
-
Dusing MR,
Florence EA,
Wiginton DA
(2001)
Pdx-1 is required for activation in vivo from a duodenum-specific enhancer.
J Biol Chem
276:14434-14444[Abstract/Free Full Text].
-
Foley J,
Cohn SL,
Salwen HR,
Chagnovich D,
Cowan J,
Mason KL,
Parysek LM
(1991)
Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line.
Cancer Res
51:6338-6345[ISI][Medline].
-
Foley J,
Ley CA,
Parysek LM
(1994)
The structure of the human peripherin gene (PRPH) and identification of potential regulatory elements.
Genomics
22:456-461[ISI][Medline].
-
Fry CJ,
Farnham PJ
(1999)
Context-dependent transcriptional regulation.
J Biol Chem
274:29583-29586[Free Full Text].
-
Gronostajski RM
(2000)
Roles of the NFI/CTF gene family in transcription and development.
Gene
249:31-45[ISI][Medline].
-
Hirota H,
Kiyama H,
Kishimoto T,
Taga T
(1996)
Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma.
J Exp Med
183:2417-2419[Free Full Text].
-
Lecomte MJ,
Basseville M,
Landon F,
Karpov V,
Fauquet M
(1998)
Transcriptional activation of the mouse peripherin gene by leukemia inhibitory factor: involvement of STAT proteins.
J Neurochem
70:971-982[ISI][Medline].
-
Lecomte MJ,
Basseville M,
Fauquet M
(1999)
Involvement of intronic sequences in cell-specific expression of the peripherin gene.
J Neurochem
73:1806-1815[Medline].
-
Leconte L,
Santha M,
Fort C,
Poujeol C,
Portier M-M,
Simonneau M
(1996)
Cell type-specific expression of the mouse peripherin gene requires both upstream and intragenic sequences in transgenic mouse embryos.
Dev Brain Res
92:1-9[Medline].
-
Leonard DG,
Ziff EB,
Greene LA
(1987)
Identifcation and characterization of mRNAs regulated by nerve growth factor in PC12 cells.
Mol Cell Bio
7:3156-3167[Abstract/Free Full Text].
-
Oblinger MM,
Wong J,
Parysek LM
(1989)
Axotomy-induced changes in the expression of a type III neuronal intermediate filament gene.
J Neurosci
9:3766-3775[Abstract].
-
Parysek LM,
Goldman RD
(1988)
Distribution of a novel 57 kDa intermediate filament (IF) protein in the nervous system.
J Neurosci
8:555-563[Abstract].
-
Portier MM,
de Nechaud B,
Gros F
(1984)
Peripherin, a new member of the intermediate filament protein family.
Dev Neurosci
6:335-344.
-
Rhodes K,
Oshima RG
(1998)
A regulatory element of the human keratin 18 gene with AP-1-dependent promoter activity.
J Biol Chem
273:26534-26542[Abstract/Free Full Text].
-
Sarkar S,
Cowan NJ
(1991)
Intragenic sequences affect the expression of the gene encoding glial fibrillary acidic protein.
J Neurochem
57:675-684[ISI][Medline].
-
Schwartz ML,
Bruce J,
Shneidman PS,
Schlaepfer WW
(1995)
Deletion of 3'-untranslated region alters the level of mRNA expression of a neurofilament light subunit transgene.
J Biol Chem
270:26364-26369[Abstract/Free Full Text].
-
Shuto T,
Horie H,
Hikawa N,
Sang K,
Tokashiki A,
Murata H,
Yamamoto I,
Ishikawa Y
(2001)
IL-6 up-regulates CNTF mRNA expression and enhances neurite regeneration.
NeuroReport
12:1081-1085[ISI][Medline].
-
Skene JH
(1989)
Axonal growth-associated proteins.
Annu Rev Neurosci
12:127-156[ISI][Medline].
-
Sterneck E,
Kaplan DR,
Johnson PF
(1996)
Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells.
J Neurochem
67:1365-1374[ISI][Medline].
-
Tanabe K,
Nakagomi S,
Kiryu-Seo S,
Namikawa K,
Imai Y,
Ochi T,
Tohyama M,
Kiyama H
(1999)
Expressed-sequence-tag approach to identify differentially expressed genes following peripheral nerve axotomy.
Mol Brain Res
64:34-40[Medline].
-
Teunissen BE,
van Amersfoorth SC,
Opthof T,
Jongsma HJ,
Bierhuizen MF
(2002)
Sp1 and Sp3 activate the rat connexin40 proximal promoter.
Biochem Biophys Res Commun
292:71-78[Medline].
-
Thompson MA,
Ziff EB
(1989)
Structure of the gene encoding peripherin, an NGF-regulated neuronal-specific type III intermediate filament protein.
Neuron
2:1043-1053[ISI][Medline].
-
Thompson MA,
Lee E,
Lawe D,
Gizang-Ginsberg E,
Ziff EB
(1992)
Nerve growth factor-induced derepression of peripherin gene expression is associated with alterations in proteins binding to a negative regulatory element.
Mol Cell Biol
12:2501-2513[Abstract/Free Full Text].
-
Vanselow J,
Grabczyk E,
Ping J,
Baetscher M,
Teng S,
Fishman MC
(1994)
GAP-43 transgenic mice: dispersed genomic sequences confer a GAP-43-like expression pattern during development and regeneration.
J Neurosci
14:499-510[Abstract].
-
Webster J,
Donofrio G,
Wallace R,
Clark AJ,
Whitelaw CB
(1997)
Intronic sequences modulate the sensitivity of
-lactoglobulin transgenes to position effects.
Gene
193:239-243[Medline]. -
Woolf CJ,
Reynolds ML,
Molander C,
O'Brien C,
Lindsay RM,
Benowitz LI
(1990)
The growth-associated protein GAP-43 appears in dorsal root ganglion cells and in the dorsal horn of the rat spinal cord following peripheral nerve injury.
Neuroscience
34:465-478[ISI][Medline].
-
Zimmerman L,
Parr B,
Lendahl U,
Cunningham M,
McKay R,
Gavin B,
Mann J,
Vassileva G,
McMahon A
(1994)
Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors.
Neuron
12:11-24[ISI][Medline].
Copyright © 2002 Society for Neuroscience 0270-6474/02/22187959-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
S. Kiryu-Seo, R. Kato, T. Ogawa, S. Nakagomi, K. Nagata, and H. Kiyama
Neuronal Injury-inducible Gene Is Synergistically Regulated by ATF3, c-Jun, and STAT3 through the Interaction with Sp1 in Damaged Neurons
J. Biol. Chem.,
March 14, 2008;
283(11):
6988 - 6996.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|